GlassScriptPhysician profile
Amitha Parvataneni
NPI 1336326362
$4,689.96
in general payments reported to CMS, 2019-2025
42 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,206 · 2021: $1,763 · 2022: $1,042 · 2024: $13.74 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.36 | 2020-2022 | |
| Esperion Therapeutics, INC. | $416.74 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $411.33 | 2020-2025 | |
| Novo Nordisk INC | $382.09 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $376.26 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $284.40 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $219.59 | 2020-2022 | |
| Amgen INC. | $212.27 | 2020-2025 | Repatha |
| Pfizer INC. | $166.75 | 2020-2025 | |
| Amarin Pharma, INC. | $149.39 | 2020-2022 | |
| Abbott Laboratories | $140.14 | 2022-2025 | Freestyle Libre 3 |
| Ucb, INC. | $102.97 | 2020-2022 | |
| Lilly USA, LLC | $78.75 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $78.33 | 2020-2022 | |
| Exact Sciences Corporation | $62.64 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitha Parvataneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.